Literature DB >> 16891496

Typing of human adenoviruses in specimens from immunosuppressed patients by PCR-fragment length analysis and real-time quantitative PCR.

Karin Ebner1, Margit Rauch, Sandra Preuner, Thomas Lion.   

Abstract

Currently, 51 human adenovirus (AdV) serotypes, which are divided into six species (A to F), are known. AdV infections are a major cause of morbidity and mortality in immunosuppressed individuals, particularly in allogeneic stem cell transplant (SCT) recipients. Any AdV species may cause life-threatening disease, but little information is available on the clinical relevance of individual serotypes. The use of serological testing for serotype identification is limited due to the impaired immune response during the posttransplant period. A new molecular approach to serotype identification is presented here that exploits variable regions within the hexon gene. All serotypes belonging to the species A, B, C, E, and F can be determined by fragment length analysis of a single PCR product. For species C, which is the most prevalent in many geographic regions, an alternative technique based on serotype-specific real-time quantitative PCR was established. Of 135 consecutive pediatric patients screened for AdV infections after allogeneic SCT, 40 tested positive. Detailed analysis revealed the presence of 10 different serotypes; serotypes 1 and 2 from species C (C01 and C02) showed the highest prevalence, accounting for 77% of the AdV-positive cases. Representatives of other species were observed less commonly: serotype A12 in 6.5%; serotype A31 in 4.5%; and B03, B16, C05, C06, D19, and F41 in 2%. The approach to rapid molecular serotype analysis presented here provides a basis for detailed studies on adenovirus epidemiology and on the transmission of nosocomial infections. Moreover, in view of the increasing importance of tailored therapy approaches, serotype identification may in the future have implications for the selection of the most appropriate antiviral treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891496      PMCID: PMC1594637          DOI: 10.1128/JCM.00048-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Rapid typing of human adenoviruses by a general PCR combined with restriction endonuclease analysis.

Authors:  A Allard; B Albinsson; G Wadell
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

2.  Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications.

Authors:  K Ebner; W Pinsker; T Lion
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  Type-specific identification of human adenovirus 3, 7, and 21 by a multiplex PCR assay.

Authors:  W Xu; D D Erdman
Journal:  J Med Virol       Date:  2001-08       Impact factor: 2.327

4.  Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease.

Authors:  Thomas Lion; Rosi Baumgartinger; Franz Watzinger; Susanne Matthes-Martin; Magdalena Suda; Sandra Preuner; Barbara Futterknecht; Anita Lawitschka; Christina Peters; Ulrike Potschger; Helmut Gadner
Journal:  Blood       Date:  2003-04-17       Impact factor: 22.113

5.  Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study.

Authors:  V Runde; S Ross; R Trenschel; E Lagemann; O Basu; K Renzing-Köhler; U W Schaefer; M Roggendorf; E Holler
Journal:  Bone Marrow Transplant       Date:  2001-07       Impact factor: 5.483

6.  Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively.

Authors:  J C De Jong; A G Wermenbol; M W Verweij-Uijterwaal; K W Slaterus; P Wertheim-Van Dillen; G J Van Doornum; S H Khoo; J C Hierholzer
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

7.  High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation.

Authors:  Marco W Schilham; Eric C Claas; Wouter van Zaane; Bianca Heemskerk; Jaak M Vossen; Arjan C Lankester; Rene E Toes; Marcela Echavarria; Aloys C Kroes; Maarten J van Tol
Journal:  Clin Infect Dis       Date:  2002-07-31       Impact factor: 9.079

Review 8.  Molecular epidemiology of adenovirus type 7 in the United States, 1966-2000.

Authors:  Dean D Erdman; Wanhong Xu; Susan I Gerber; Gregory C Gray; David Schnurr; Adriana E Kajon; Larry J Anderson
Journal:  Emerg Infect Dis       Date:  2002-03       Impact factor: 6.883

Review 9.  The impact of adenovirus infection on the immunocompromised host.

Authors:  Tsoline Kojaoghlanian; Phyllis Flomenberg; Marshall S Horwitz
Journal:  Rev Med Virol       Date:  2003 May-Jun       Impact factor: 6.989

10.  Clinical assessment of a generic DNA amplification assay for the identification of respiratory adenovirus infections.

Authors:  S Mitchell; H J O'Neill; G M Ong; S Christie; P Duprex; D E Wyatt; C McCaughey; V J Armstrong; S Feeney; L Metwally; P V Coyle
Journal:  J Clin Virol       Date:  2003-04       Impact factor: 3.168

View more
  22 in total

Review 1.  Diagnosis of hepatitis via nanomaterial-based electrochemical, optical or piezoelectrical biosensors: a review on recent advancements.

Authors:  Soodabeh Hassanpour; Behzad Baradaran; Miguel de la Guardia; Amir Baghbanzadeh; Jafar Mosafer; Maryam Hejazi; Ahad Mokhtarzadeh; Mohammad Hasanzadeh
Journal:  Mikrochim Acta       Date:  2018-12-01       Impact factor: 5.833

Review 2.  Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients.

Authors:  S Samuel Weigt; Aric L Gregson; Jane C Deng; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2011-08-19       Impact factor: 3.119

Review 3.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

Review 4.  p53 gene in treatment of hepatic carcinoma: status quo.

Authors:  Yong-Song Guan; Zi La; Lin Yang; Qing He; Ping Li
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

5.  Quantitative real-time PCR assay panel for detection and type-specific identification of epidemic respiratory human adenoviruses.

Authors:  Xiaoyan Lu; Elizabeth Trujillo-Lopez; Lisa Lott; Dean D Erdman
Journal:  J Clin Microbiol       Date:  2013-01-16       Impact factor: 5.948

6.  Identification of adenoviruses in specimens from high-risk pediatric stem cell transplant recipients and controls.

Authors:  Xiaotian Zheng; Xiaoyan Lu; Dean D Erdman; Evan J Anderson; Judith A Guzman-Cottrill; Morris Kletzel; Ben Z Katz
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

Review 7.  The challenge for gene therapy: innate immune response to adenoviruses.

Authors:  Bart Thaci; Ilya V Ulasov; Derek A Wainwright; Maciej S Lesniak
Journal:  Oncotarget       Date:  2011-03

8.  Investigation of adenovirus occurrence in pediatric tumor entities.

Authors:  Karin Kosulin; Christine Haberler; Johannes A Hainfellner; Gabriele Amann; Susanna Lang; Thomas Lion
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

9.  Development of multiplexed real-time quantitative polymerase chain reaction assay for detecting human adenoviruses.

Authors:  Meei-Li Huang; Long Nguy; James Ferrenberg; Michael Boeckh; Anne Cent; Lawrence Corey
Journal:  Diagn Microbiol Infect Dis       Date:  2008-08-15       Impact factor: 2.803

10.  Evaluation and validation of a real-time PCR assay for detection and quantitation of human adenovirus 14 from clinical samples.

Authors:  David Metzgar; Greg Skochko; Carl Gibbins; Nolan Hudson; Lisa Lott; Morris S Jones
Journal:  PLoS One       Date:  2009-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.